ArticleThe Journal of antimicrobial chemotherapy2018
Duration of exposure to multiple antibiotics is associated with increased risk of VRE bacteraemia: a nested case-control study.
Article in The Journal of antimicrobial chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Sex differences in vancomycin-resistant enterococci bloodstream infections-a systematic review and meta-analysis.Biology of sex differences · 2021Pooled it
- Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin: A Randomized Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Trial
- Randomized Trial Evaluating Clinical Impact of RAPid IDentification and Susceptibility Testing for Gram-negative Bacteremia: RAPIDS-GN.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Trial
- Dynamic screening strategies for the control of a prolonged vancomycin-resistant enterococci outbreak: A decade-long study in a Japanese tertiary hospital.Epidemiology and infection · 2026Article
- Analysis of Antibiotic Consumption Trends and Pathogens' Epidemiological Profile Within a Multidisciplinary Clinical Hospital from Romania.Antibiotics (Basel, Switzerland) · 2026Article
- Clinical management ofEClinicalMedicine · 2025Article
- Utilization of broad- versus narrow-spectrum antibiotics for the treatment of outpatient community-acquired pneumonia among adults in the United States.Pharmacoepidemiology and drug safety · 2024Article
- Adaptation and validation of a quantitative vanA/vanB DNA screening assay on a high-throughput PCR system.Scientific reports · 2024Article
- Article
- Vancomycin resistant enterococcus risk factors for hospital colonization in hematological patients: a matched case-control study.Antimicrobial resistance and infection control · 2023Article
- The intestinal carrier status of Enterococcus spp. in children: clonal diversity and alterations in resistance phenotypes before and after admission to a pediatric intensive care unit.BMC pediatrics · 2023Article
- Antibiotic choice for Group B Streptococcus prophylaxis in mothers with reported penicillin allergy and associated newborn outcomes.BMC pregnancy and childbirth · 2023Article
- Utilization of nonguideline concordant antibiotic treatment following acute otitis media in children in the United States.Pharmacoepidemiology and drug safety · 2023Article
- Antibiotic Prescribing in Outpatient Settings: Rural Patients Are More Likely to Receive Fluoroquinolones and Longer Antibiotic Courses.Antibiotics (Basel, Switzerland) · 2023Article
- Clinical Impact of Vancomycin Treatment in Ampicillin-Susceptible Enterococci Bloodstream Infections.Antibiotics (Basel, Switzerland) · 2022Article
- Antibiotic Stewardship Related to Delayed Diagnosis and Poor Prognosis of Critically Ill Patients with Vancomycin-Resistant Enterococcal Bacteremia: A Retrospective Cohort Study.Infection and drug resistance · 2022Article
- Duration of Outpatient Antibiotic Therapy for Common Outpatient Infections, 2017.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Development and Validation of a Machine Learning Model to Estimate Bacterial Sepsis Among Immunocompromised Recipients of Stem Cell Transplant.JAMA network open · 2021Observational
- Optimising efficacy of antibiotics against systemic infection by varying dosage quantities and times.PLoS computational biology · 2020Article
- Antimicrobial Resistance in ESKAPE Pathogens.Clinical microbiology reviews · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
Background: VRE bacteraemia has a high mortality and continues to defy control. Antibiotic risk factors for VRE bacteraemia have not been adequately defined. We aimed to determine the risk factors for VRE bacteraemia focusing on duration of antibiotic exposure. Methods: A retrospective matched nested case-control study was conducted amongst hospitalized patients at Cambridge University Hospitals NHS Foundation Trust (CUH) from 1 January 2006 to 31 December 2012. Cases who developed a first episode of VRE bacteraemia were matched 1:1 to controls by length of stay, year, specialty and ward type. Independent risk factors for VRE bacteraemia were evaluated using conditional logistic regression. Results: Two hundred and thirty-five cases were compared with 220 controls. Duration of exposure to parenteral vancomycin, fluoroquinolones and meropenem was independently associated with VRE bacteraemia. Compared with patients with no exposure to vancomycin, those who received courses of 1-3 days, 4-7 days or >7 days had a stepwise increase in risk of VRE bacteraemia [conditional OR (cOR) 1.2 (95% CI 0.4-3.8), 3.8 (95% CI 1.2-11.7) and 6.6 (95% CI 1.9-22.8), respectively]. Other risk factors were: presence of a central venous catheter (CVC) [cOR 8.7 (95% CI 2.6-29.5)]; neutropenia [cOR 15.5 (95% CI 4.2-57.0)]; hypoalbuminaemia [cOR 8.5 (95% CI 2.4-29.5)]; malignancy [cOR 4.4 (95% CI 1.6-12.0)]; gastrointestinal disease [cOR 12.4 (95% CI 4.2-36.8)]; and hepatobiliary disease [cOR 7.9 (95% CI 2.1-29.9)]. Conclusions: Longer exposure to vancomycin, fluoroquinolones or meropenem was associated with VRE bacteraemia. Antimicrobial stewardship interventions targeting high-risk antibiotics are required to complement infection control procedures against VRE bacteraemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.